Aromatase inhibitor-associated bone fractures: A case-cohort GWAS and functional genomics

Mohan Liu, Paul E. Goss, James N. Ingle, Michiaki Kubo, Yoichi Furukawa, Anthony Batzler, Gregory D. Jenkins, Erin E. Carlson, Yusuke Nakamura, Daniel J Schaid, Judy Anne W Chapman, Lois E. Shepherd, Matthew J. Ellis, Sundeep Khosla, Liewei M Wang, Richard M Weinshilboum

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Bone fractures are a major consequence of osteoporosis. There is a direct relationship between serum estrogen concentrations and osteoporosis risk. Aromatase inhibitors (AIs) greatly decrease serum estrogen levels in postmenopausal women, and increased incidence of fractures is a side effect of AI therapy. We performed a discovery case-cohort genome-wide association study (GWAS) using samples from 1071 patients, 231 cases and 840 controls, enrolled in the MA.27 breast cancer AI trial to identify genetic factors involved in AI-related fractures, followed by functional genomic validation. Association analyses identified 20 GWAS single nucleotide polymorphism (SNP) signals with P < 5E-06. After removal of signals in gene deserts and those composed entirely of imputed SNPs, we applied a functional validation “decision cascade” that resulted in validation of the CTSZ-SLMO2-ATP5E, TRAM2-TMEM14A, and MAP4K4 genes. These genes all displayed estradiol (E2)-dependent induction in human fetal osteoblasts transfected with estrogen receptor-α, and their knockdown altered the expression of known osteoporosisrelated genes. These same genes also displayed SNP-dependent variation in E2 induction that paralleled the SNP-dependent induction of known osteoporosis genes, such as osteoprotegerin. In summary, our case-cohort GWAS identified SNPs in or near CTSZ-SLMO2-ATP5E, TRAM2- TMEM14A, and MAP4K4 that were associated with risk for bone fracture in estrogen receptorpositive breast cancer patients treated with AIs. These genes displayed E2-dependent induction, their knockdown altered the expression of genes related to osteoporosis, and they displayed SNP genotype-dependent variation in E2 induction. These observations may lead to the identification of novel mechanisms associated with fracture risk in postmenopausal women treated with AIs.

Original languageEnglish (US)
Pages (from-to)1740-1751
Number of pages12
JournalMolecular Endocrinology
Volume28
Issue number10
DOIs
StatePublished - Oct 1 2014

Fingerprint

Aromatase Inhibitors
Genome-Wide Association Study
Bone Fractures
Genomics
Single Nucleotide Polymorphism
Osteoporosis
Genes
Estrogens
Breast Neoplasms
Osteoprotegerin
Serum
Osteoblasts
Estrogen Receptors
Estradiol
Genotype
Gene Expression
Incidence

ASJC Scopus subject areas

  • Molecular Biology
  • Endocrinology

Cite this

Aromatase inhibitor-associated bone fractures : A case-cohort GWAS and functional genomics. / Liu, Mohan; Goss, Paul E.; Ingle, James N.; Kubo, Michiaki; Furukawa, Yoichi; Batzler, Anthony; Jenkins, Gregory D.; Carlson, Erin E.; Nakamura, Yusuke; Schaid, Daniel J; Chapman, Judy Anne W; Shepherd, Lois E.; Ellis, Matthew J.; Khosla, Sundeep; Wang, Liewei M; Weinshilboum, Richard M.

In: Molecular Endocrinology, Vol. 28, No. 10, 01.10.2014, p. 1740-1751.

Research output: Contribution to journalArticle

Liu, M, Goss, PE, Ingle, JN, Kubo, M, Furukawa, Y, Batzler, A, Jenkins, GD, Carlson, EE, Nakamura, Y, Schaid, DJ, Chapman, JAW, Shepherd, LE, Ellis, MJ, Khosla, S, Wang, LM & Weinshilboum, RM 2014, 'Aromatase inhibitor-associated bone fractures: A case-cohort GWAS and functional genomics', Molecular Endocrinology, vol. 28, no. 10, pp. 1740-1751. https://doi.org/10.1210/me.2014-1147
Liu, Mohan ; Goss, Paul E. ; Ingle, James N. ; Kubo, Michiaki ; Furukawa, Yoichi ; Batzler, Anthony ; Jenkins, Gregory D. ; Carlson, Erin E. ; Nakamura, Yusuke ; Schaid, Daniel J ; Chapman, Judy Anne W ; Shepherd, Lois E. ; Ellis, Matthew J. ; Khosla, Sundeep ; Wang, Liewei M ; Weinshilboum, Richard M. / Aromatase inhibitor-associated bone fractures : A case-cohort GWAS and functional genomics. In: Molecular Endocrinology. 2014 ; Vol. 28, No. 10. pp. 1740-1751.
@article{4bb25972f689443aa588cb1b87a5a3de,
title = "Aromatase inhibitor-associated bone fractures: A case-cohort GWAS and functional genomics",
abstract = "Bone fractures are a major consequence of osteoporosis. There is a direct relationship between serum estrogen concentrations and osteoporosis risk. Aromatase inhibitors (AIs) greatly decrease serum estrogen levels in postmenopausal women, and increased incidence of fractures is a side effect of AI therapy. We performed a discovery case-cohort genome-wide association study (GWAS) using samples from 1071 patients, 231 cases and 840 controls, enrolled in the MA.27 breast cancer AI trial to identify genetic factors involved in AI-related fractures, followed by functional genomic validation. Association analyses identified 20 GWAS single nucleotide polymorphism (SNP) signals with P < 5E-06. After removal of signals in gene deserts and those composed entirely of imputed SNPs, we applied a functional validation “decision cascade” that resulted in validation of the CTSZ-SLMO2-ATP5E, TRAM2-TMEM14A, and MAP4K4 genes. These genes all displayed estradiol (E2)-dependent induction in human fetal osteoblasts transfected with estrogen receptor-α, and their knockdown altered the expression of known osteoporosisrelated genes. These same genes also displayed SNP-dependent variation in E2 induction that paralleled the SNP-dependent induction of known osteoporosis genes, such as osteoprotegerin. In summary, our case-cohort GWAS identified SNPs in or near CTSZ-SLMO2-ATP5E, TRAM2- TMEM14A, and MAP4K4 that were associated with risk for bone fracture in estrogen receptorpositive breast cancer patients treated with AIs. These genes displayed E2-dependent induction, their knockdown altered the expression of genes related to osteoporosis, and they displayed SNP genotype-dependent variation in E2 induction. These observations may lead to the identification of novel mechanisms associated with fracture risk in postmenopausal women treated with AIs.",
author = "Mohan Liu and Goss, {Paul E.} and Ingle, {James N.} and Michiaki Kubo and Yoichi Furukawa and Anthony Batzler and Jenkins, {Gregory D.} and Carlson, {Erin E.} and Yusuke Nakamura and Schaid, {Daniel J} and Chapman, {Judy Anne W} and Shepherd, {Lois E.} and Ellis, {Matthew J.} and Sundeep Khosla and Wang, {Liewei M} and Weinshilboum, {Richard M}",
year = "2014",
month = "10",
day = "1",
doi = "10.1210/me.2014-1147",
language = "English (US)",
volume = "28",
pages = "1740--1751",
journal = "Molecular Endocrinology",
issn = "0888-8809",
publisher = "The Endocrine Society",
number = "10",

}

TY - JOUR

T1 - Aromatase inhibitor-associated bone fractures

T2 - A case-cohort GWAS and functional genomics

AU - Liu, Mohan

AU - Goss, Paul E.

AU - Ingle, James N.

AU - Kubo, Michiaki

AU - Furukawa, Yoichi

AU - Batzler, Anthony

AU - Jenkins, Gregory D.

AU - Carlson, Erin E.

AU - Nakamura, Yusuke

AU - Schaid, Daniel J

AU - Chapman, Judy Anne W

AU - Shepherd, Lois E.

AU - Ellis, Matthew J.

AU - Khosla, Sundeep

AU - Wang, Liewei M

AU - Weinshilboum, Richard M

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Bone fractures are a major consequence of osteoporosis. There is a direct relationship between serum estrogen concentrations and osteoporosis risk. Aromatase inhibitors (AIs) greatly decrease serum estrogen levels in postmenopausal women, and increased incidence of fractures is a side effect of AI therapy. We performed a discovery case-cohort genome-wide association study (GWAS) using samples from 1071 patients, 231 cases and 840 controls, enrolled in the MA.27 breast cancer AI trial to identify genetic factors involved in AI-related fractures, followed by functional genomic validation. Association analyses identified 20 GWAS single nucleotide polymorphism (SNP) signals with P < 5E-06. After removal of signals in gene deserts and those composed entirely of imputed SNPs, we applied a functional validation “decision cascade” that resulted in validation of the CTSZ-SLMO2-ATP5E, TRAM2-TMEM14A, and MAP4K4 genes. These genes all displayed estradiol (E2)-dependent induction in human fetal osteoblasts transfected with estrogen receptor-α, and their knockdown altered the expression of known osteoporosisrelated genes. These same genes also displayed SNP-dependent variation in E2 induction that paralleled the SNP-dependent induction of known osteoporosis genes, such as osteoprotegerin. In summary, our case-cohort GWAS identified SNPs in or near CTSZ-SLMO2-ATP5E, TRAM2- TMEM14A, and MAP4K4 that were associated with risk for bone fracture in estrogen receptorpositive breast cancer patients treated with AIs. These genes displayed E2-dependent induction, their knockdown altered the expression of genes related to osteoporosis, and they displayed SNP genotype-dependent variation in E2 induction. These observations may lead to the identification of novel mechanisms associated with fracture risk in postmenopausal women treated with AIs.

AB - Bone fractures are a major consequence of osteoporosis. There is a direct relationship between serum estrogen concentrations and osteoporosis risk. Aromatase inhibitors (AIs) greatly decrease serum estrogen levels in postmenopausal women, and increased incidence of fractures is a side effect of AI therapy. We performed a discovery case-cohort genome-wide association study (GWAS) using samples from 1071 patients, 231 cases and 840 controls, enrolled in the MA.27 breast cancer AI trial to identify genetic factors involved in AI-related fractures, followed by functional genomic validation. Association analyses identified 20 GWAS single nucleotide polymorphism (SNP) signals with P < 5E-06. After removal of signals in gene deserts and those composed entirely of imputed SNPs, we applied a functional validation “decision cascade” that resulted in validation of the CTSZ-SLMO2-ATP5E, TRAM2-TMEM14A, and MAP4K4 genes. These genes all displayed estradiol (E2)-dependent induction in human fetal osteoblasts transfected with estrogen receptor-α, and their knockdown altered the expression of known osteoporosisrelated genes. These same genes also displayed SNP-dependent variation in E2 induction that paralleled the SNP-dependent induction of known osteoporosis genes, such as osteoprotegerin. In summary, our case-cohort GWAS identified SNPs in or near CTSZ-SLMO2-ATP5E, TRAM2- TMEM14A, and MAP4K4 that were associated with risk for bone fracture in estrogen receptorpositive breast cancer patients treated with AIs. These genes displayed E2-dependent induction, their knockdown altered the expression of genes related to osteoporosis, and they displayed SNP genotype-dependent variation in E2 induction. These observations may lead to the identification of novel mechanisms associated with fracture risk in postmenopausal women treated with AIs.

UR - http://www.scopus.com/inward/record.url?scp=84907661509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907661509&partnerID=8YFLogxK

U2 - 10.1210/me.2014-1147

DO - 10.1210/me.2014-1147

M3 - Article

C2 - 25148458

AN - SCOPUS:84907661509

VL - 28

SP - 1740

EP - 1751

JO - Molecular Endocrinology

JF - Molecular Endocrinology

SN - 0888-8809

IS - 10

ER -